EVENTS529
ARTICLES254
CATEGORYMedical
Active
Phase II/III clinical trial readouts from publicly traded biotech companies. Primary endpoints, safety signals, and regulatory pathway updates.
LATEST EVENTS
| Entity | Type | Summary | Impact | Confidence |
|---|---|---|---|---|
| Abivax | product | Abivax's stock rebounded after releasing reassuring safety data for its colitis drug candidate. | medium | 90% |
| Roche | product | Roche's investigational KRAS G12C inhibitor achieved a Phase 3 win against competitors Amgen and BMS in lung cancer. | high | 90% |
| Kura Oncology, Kyowa Kirin | regulatory | FDA accepted Kura Oncology and Kyowa Kirin's NDA for ziftomenib with priority review, setting a PDUFA date of November 3… | high | 100% |
| Capricor Therapeutics | regulatory | Capricor Therapeutics announced an extension of the PDUFA target action date for its Deramiocel BLA to November 22, 2026… | medium | 100% |
| Abivax | product | Abivax's stock rebounded following reassuring safety data for its colitis prospect from a clinical trial. | medium | 100% |
| Roche | product | Roche's investigational KRAS G12C inhibitor achieved a Phase 3 clinical trial win against competitors Amgen and Bristol … | high | 100% |
| National Security Commission on Emerging Biotechnology (NSCEB) | regulatory | The NSCEB is reviewing how biotech advancements will shape national defense, with a comprehensive report due to Congress… | medium | 90% |
| Biotech Clinical Laboratories, Inc. | product | Biotech Clinical Laboratories, Inc. operates a CAP Accredited, 24-hour full-service laboratory offering COVID-19 and tox… | medium | 90% |
| BioTech X-ray Inc. | product | BioTech X-ray Inc. provides mobile diagnostic imaging services, offering cost-efficient, patient-first care at the bedsi… | medium | 90% |
| Novocure | announcement | Novocure announced it will report Q2 2026 financial results on July 23, 2026. | low | 90% |
| Novocure | regulatory | Novocure received CE Mark for Optune Pax® for locally advanced pancreatic cancer, with Germany as the first EU launch ma… | high | 95% |
| Novocure | financial | Novocure reported Q2 2026 financial results, with net revenues of $184 million, a 16% increase year-over-year. | medium | 95% |
| Bristol-Myers Squibb | regulatory | FDA decision expected on March 6, 2026, for Bristol-Myers Squibb's deucravacitinib (Sotyktu) sNDA for psoriatic arthriti… | medium | 90% |
| Merck | earnings | Merck announced its Second-Quarter 2026 financial results and highlighted key regulatory and clinical milestones. | medium | 100% |
| Merck | regulatory | U.S. FDA accepted Merck's sBLA for ENFLONSIA (clesrovimab-cfor) to update its RSV indication for children under two. | medium | 100% |
| BMS, BioNTech | partnership | BMS and BioNTech announced an $11.1 billion licensing agreement, contributing to the record-breaking biopharma market. | high | 90% |
| GSK, Hengrui | partnership | GSK and Hengrui formed a licensing partnership valued over $12 billion, part of a significant increase in deal sizes. | high | 90% |
| AstraZeneca, CSPC | partnership | AstraZeneca and CSPC entered an $18.5 billion licensing deal, contributing to the booming biopharma licensing market. | high | 90% |
| REGENXBIO Inc. | product | REGENXBIO announced positive 12-month pivotal data from its Phase I/II/III CAMPSIITE® trial of RGX-121 for MPS II, meeti… | high | 98% |
| Alessa Therapeutics | regulatory | Alessa Therapeutics' enzalutamide implants (Enolen) received FDA Fast Track designation for prostate cancer. | medium | 95% |
WATCHER CONFIG
query: biotech clinical trial results phase III primary endpoint FDA approval PDUFA safety data
event_types: ['product', 'regulatory', 'financial']
impact_floor: medium
time_window: 7
Signal event details
Biotech Clinical Trial Results
FIELD DATA
RAW DATA